Immuno-oncology Therapy for Metastatic Triple-Negative Breast Cancer: Emerging Clinical Data and Payer Considerations

Immuno-oncology Therapy for Metastatic Triple-Negative Breast Cancer: Emerging Clinical Data and Payer Considerations

Faculty Presenters

Laura R. Bobolts, PharmD, BCOP
SVP, Clinical Strategy and Growth
Oncology Analytics, Inc.
Nova Southeastern University,
College of Pharmacy
Ft. Lauderdale, Florida

Allison Schepers, PharmD, BCOP
Clinical Pharmacist Specialist, Oncology
University of Michigan - Michigan Medicine
Ann Arbor, Michigan

Brandy Strickland Snyder, PharmD, MBA, BCOP
Pharmacy Director II, Hematology/Oncology   
and Investigational Drug Services
Wake Forest Baptist Health
Winston-Salem, North Carolina
 

Program Description
Patients with triple-negative breast cancer (TNBC) have a poor prognosis and overall survival of just 18 months or less, indicating an urgent need for targeted and immunotherapy options such as PARP inhibitors, AKT inhibitors, and MEK inhibitors in combination with immune checkpoint inhibitors and chemotherapy. Presence of PD-L1 expression in TNBC may help predict response and efficacy of immunotherapy agents for patients. However, the aggressive nature of TNBC presents challenges for managed care professionals regarding management of and access to oncology agents. As clinical data rapidly emerges, managed care organizations must ensure these therapy options are available on medical formulary benefits. The expert panelists will discuss strategies to address complex utilization management issues, such as comparison and selection of preferred agents for formulary decisions, step therapy requirements, and value-based payment models employed to improve patient outcomes and mitigate costs.

Target Audience: Managed care and oncology pharmacists
Type of Activity: Application
Release date: June 29, 2021
Expiration date: December 29, 2021
Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives
At the completion of this activity, participants will be able to:

• Compare drug therapy options and strategies for available and emerging treatments involving immune checkpoint inhibitors (ICIs) for the treatment of metastatic triple-negative breast cancer (mTNBC)
• Examine common payer challenges to the management of oncology agents
• Identify implementation strategies for current and emerging ICI therapy for mTNBC

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-21-269-H01-P. The activity is available for CE credit through December 29, 2021.


Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
 

---

Disclosures

Faculty

Laura R. Bobolts, PharmD, BCOP, Allison Schepers, PharmD, BCOP, and Brandy Strickland Snyder, PharmD, MBA, BCOP have no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Amy Seung, PharmD, BCOP, FHOPA; Liz Rauh; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers are used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this live CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms